Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,740,674
  • Shares Outstanding, K 28,761
  • Annual Sales, $ 50,700 K
  • Annual Income, $ 10,930 K
  • EBIT $ 27 M
  • EBITDA $ 31 M
  • 60-Month Beta 0.80
  • Price/Sales 91.24
  • Price/Cash Flow N/A
  • Price/Book 5.22

Options Overview Details

View History
  • Implied Volatility 45.40% ( -0.59%)
  • Historical Volatility 55.49%
  • IV Percentile 36%
  • IV Rank 20.33%
  • IV High 89.43% on 02/16/24
  • IV Low 34.16% on 11/14/24
  • Put/Call Vol Ratio 0.66
  • Today's Volume 839
  • Volume Avg (30-Day) 287
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 11,151
  • Open Int (30-Day) 9,253

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.25
  • Number of Estimates 4
  • High Estimate 1.81
  • Low Estimate 0.96
  • Prior Year 0.30
  • Growth Rate Est. (year over year) +316.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
155.16 +6.23%
on 12/19/24
200.00 -17.58%
on 11/29/24
-13.27 (-7.45%)
since 11/20/24
3-Month
155.16 +6.23%
on 12/19/24
207.84 -20.69%
on 11/11/24
-19.34 (-10.50%)
since 09/20/24
52-Week
107.50 +53.33%
on 02/22/24
219.34 -24.85%
on 07/26/24
+51.89 (+45.94%)
since 12/20/23

Most Recent Stories

More News
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Krystal Biotech KRYS announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The...

KRYS : 164.83 (+2.49%)
CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Krystal Biotech Reports Preliminary Clinical Results for Inhaled KB707 in Advanced NSCLC Patients with 27% Objective Response Rate

Initial clinical results show inhaled KB707 achieved 27% ORR and 73% DCR in advanced NSCLC patients.Quiver AI SummaryKrystal Biotech, Inc. announced preliminary clinical data from its KYANITE-1 study,...

KRYS : 164.83 (+2.49%)
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

KRYS : 164.83 (+2.49%)
Insider Sale: President of $KRYS (KRYS) Sells 911 Shares

Suma Krishnan, the President of $KRYS ($KRYS), sold 911 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.1% of their shares....

KRYS : 164.83 (+2.49%)
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating...

KRYS : 164.83 (+2.49%)
CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Krystal Biotech Announces Promising Clinical Data for KB408 Gene Therapy in Alpha-1 Antitrypsin Deficiency Patients and Progress on KB407 for Cystic Fibrosis

Krystal Biotech reports positive clinical data for KB408 and KB407, demonstrating safety and efficacy in AATD and cystic fibrosis patients.Quiver AI SummaryKrystal Biotech, Inc. has announced promising...

KRYS : 164.83 (+2.49%)
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

KRYS : 164.83 (+2.49%)
Krystal Biotech Provides Update on B-VEC EMA Review Timeline and Plans for German Market Launch

Krystal Biotech anticipates CHMP opinion in Q1 2025 and plans German launch of B-VEC for DEB in Q2 2025.Quiver AI SummaryKrystal Biotech, Inc. announced that the European Medicines Agency’s Committee...

KRYS : 164.83 (+2.49%)
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

KRYS : 164.83 (+2.49%)
Krystal Biotech, Inc. CEO to Participate in Investor Conferences in December 2024

Krystal Biotech's CEO to participate in investor conferences on December 3 and 4, 2024, with live webcasts available.Quiver AI SummaryKrystal Biotech, Inc. announced that CEO Krish S. Krishnan will participate...

KRYS : 164.83 (+2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 174.25
2nd Resistance Point 170.12
1st Resistance Point 167.47
Last Price 164.83
1st Support Level 160.69
2nd Support Level 156.56
3rd Support Level 153.91

See More

52-Week High 219.34
Fibonacci 61.8% 176.62
Last Price 164.83
Fibonacci 50% 163.42
Fibonacci 38.2% 150.22
52-Week Low 107.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar